Patients with cirrhosis may display impaired or enhanced platelet activation, but the reasons for these equivocal findings are unclear. We investigated if bacterial lipopolysaccharide (LPS) is implicated in platelet activation. In a cross-sectional study, conducted in an ambulatory care clinic and hospital, comparing 69 cirrhosis patients and 30 controls matched for sex, age, and atherosclerotic risk factors, serum levels of LPS, soluble cluster of differentiation 40 ligand and p-selectin (two markers of platelet activation), and zonulin (a marker of gut permeability) were investigated. Ex vivo and in vitro studies were also performed to explore the effect of LPS on platelet activation. Compared to controls, cirrhosis patients displayed higher serum levels of .2] pg/mL, P < 0.0001), soluble cluster of differentiation 40 ligand (7.0 6 2.2 versus 24.4 6 13.3 ng/mL, P < 0.0001), soluble p-selectin (14.2 6 4.05 versus 33.2 6 15.2 ng/mL, P < 0.0001), and zonulin (1.87 6 0.84 versus 2.54 6 0.94 ng/mL, P < 0.006). LPS significantly correlated with zonulin (r 5 0.45, P < 0.001). Ex vivo studies showed that platelets from cirrhosis patients were more responsive to the agonists independently from platelet count; this phenomenon was blunted by incubation with an inhibitor of Toll-like receptor 4. In vitro study by normal platelets showed that LPS alone (50-150 pg/mL) did not stimulate platelets but amplified platelet response to the agonists; Toll-like receptor 4 inhibitor blunted this effect. Conclusion: LPS may be responsible for platelet activation and potentially contributes to thrombotic complications occurring in cirrhosis. ( 
F
or decades, liver cirrhosis (LC) was believed to be associated with an elevated risk of bleeding, which was apparently dependent on prolongation of global clotting test, hyperfibrinolysis, and thrombocytopenia. (1, 2) For this reason, the term "coagulopathy" has been coined to indicate that cirrhosis patients bleed because of the existence of clotting abnormalities. (3) This term has been recently challenged because spontaneous bleeding is not frequent in LC and both spontaneous and provoked bleedings are unrelated to clotting changes. (4) Conversely, there is a growing body of evidence that cirrhosis patients suffer from thrombosis in the portal and systemic circulation.
(5) Such a relationship is biologically supported by previous data showing that cirrhosis is complicated with an ongoing prothrombotic state, a phenomenon putatively related to a low-grade endotoxemia likely originating from enhanced gut permeability. (6, 7) Regarding platelet function recent studies have negated the existence of a thrombocytopathy and demonstrated, conversely, that LC is associated with platelet hyperfunction (8, 9) ; the underlying mechanism, however, is still to be elucidated. We speculated that, as for clotting system, low-grade endotoxemia might represent a trigger for platelet activation as studies have demonstrated, even if not univocally, that bacterial lipopolysaccharides (LPS) triggers platelet activation. (10) (11) (12) (13) To explore this issue, we measured serum levels of Abbreviations: ADP, adenosine diphosphate; CD40L, cluster of differentiation 40 ligand; HS, healthy subjects; LC, liver cirrhosis; LPS, lipopolysaccharide; mAb, monoclonal antibody; PA, platelet aggregation; PRP, platelet-rich plasma; sCD40L, soluble CD40L; sPs, soluble p-selectin; STC, subthreshold concentration; TC, threshold concentration; TLR4, Toll-like receptor 4; TLR4bp, TLR4 inhibitor peptide.
LPS and two markers of platelet activation, soluble cluster of differentiation 40 ligand (sCD40L) and soluble p-selectin (sPs), in a population with LC and in a control group. Furthermore, we performed ex vivo study to evaluate platelet aggregation (PA) in response to subthreshold concentrations (STCs) of common agonists in platelets from cirrhosis patients and controls. Finally, we performed an in vitro study to assess if LPS, at concentration detected in the peripheral circulation of cirrhosis patients, affects PA in platelet from healthy subjects (HS).
Materials and Methods

STUDY POPULATION
Consecutive patients with biopsy-proven cirrhosis of various causes, aged 18 years or above, were recruited after giving written informed consent at the Internal Medicine Unit and Gastroenterological Unit of Sapienza University of Rome, Italy.
The ethical committee of our institution approved the study. This study was conducted according to the principles stated in the Declaration of Helsinki.
Exclusion criteria were (1) overt infection or sepsis; (2) treatment with systemic or nonabsorbable antibiotic, aspirin, other nonsteroidal anti-inflammatory drugs, or antidepressant drugs in the previous 30 days; (3) recent need of transfusion of platelets or plasma; (4) presence of extrahepatic malignancy; (5) active alcohol intake in the last 6 months; and (6) pregnancy or breast-feeding.
Sixty-nine patients fulfilled these criteria and entered the study. As a control group, 30 patients (mean age 68 6 5 years, 67% male) were selected; they were matched for presence of concomitant cardiovascular disease (in LC 5 18% versus in controls 5 35%, P 5 0.1274) and of diabetes (in LC 5 30% versus in controls 5 20%, P 5 0.3034). Neither LC patients nor controls were taking any drug that would interfere with platelet function.
The study encompassed several phases, including (1) analysis of serum LPS and two markers of platelet activation, sCD40L and sPs, in LC patients and matched controls; (2) ex vivo PA in 15 LC patients (13 males, 2 females, age 60.9 6 12.4 years) and 10 controls (6 males, 4 females, age 51.0 67.0 years); (3) ex vivo PA in LC (n 5 6, 4 males, 2 females, age 52.5 6 11.2 years) with platelet count <50 3 10 3 /lL and in controls (n 5 5, 2 males, 3 females, age 58.8 6 17.4 years) with platelet count >150 3 10 3 /lL; and (4) in vitro study with platelets from HS (n 5 5, 3 males, 2 females, age 43.0 6 8.6) stimulated with LPS concentrations similar to those detected in the peripheral circulation of LC patients.
LABORATORY METHODS
Measurements were ascertained while blinded to the sample origin. All samples were assayed in duplicate, and those showing values above the standard curve were retested with appropriate dilutions.
Routine biochemical tests were carried out using standard procedures.
Patients had fasted for the last 12 hours before blood sampling. Blood was collected in BD Vacutainer (Franklin Lakes, NJ) between 8:00 and 9:00 AM, and patients underwent routine biochemical evaluations including serum creatinine, serum albumin, serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, bilirubin, platelet count, and prothrombin time.
citrate) were centrifuged for 15 minutes at 180g. To avoid leukocyte contamination, only the top 75% of the PRP was collected, according to Pignatelli et al. (14) To perform ex vivo aggregation tests, PRP from controls was diluted with Tyrode buffer to obtain the same platelet count of cirrhosis patients; platelet count from cirrhosis patients ranged from 31 to 145 3 10 3 /lL. For in vitro experiments performed in HS, the platelet count was adjusted to 200 3 10 3 /lL. PRP samples were preincubated with or without Toll-like receptor (TLR) 4 inhibitor peptide (TLR4bp) (4 lM; Novus Biologicals) or control peptide (4 lM; Novus Biologicals) (20 minutes at 378C) and then treated with or without LPS (50-150 pg/mL) from Escherichia coli 0111:B4 (Sigma-Aldrich, St. Louis, MO), for 5 minutes before activation with collagen (0.25 lg/mL; Mascia Brunelli, Milan, Italy) or adenosine diphosphate (ADP) (0.4 lM; Sigma-Aldrich) for 10 minutes. After activation, samples were centrifuged for 3 minutes at 3,000g. Supernatants were stored at 2808C for analysis of platelet CD40L and P-selectin.
Platelet Aggregation
PA was measured with a light transmission aggregometer (Cronolog). PA was induced by STC (0.25 lg/ mL) of collagen or (0.4 lM) ADP in the presence or absence of LPS (50-150 pg/mL), TLR4bp (4 lM), or control peptide (4 lM) and measured as described. (15) The STC of agonists was defined as the highest concentration that elicited <20% PA. PA was also induced with a threshold concentration (TC; 2 lg/ mL) of collagen; unstimulated PRP was used as control.
Flow-Cytometric Analysis of PlateletMonocyte Complex and TLR4 Expression
Platelet-monocyte complex was analyzed with specific fluorescein isothiocyanate-labeled monoclonal antibody (mAb) or phycoerythrin-labeled mAb. In particular, we used mAbs anti-CD61-phycoerythrin (Beckman Coulter) and anti-CD14-fluorescein isothiocyanate (Beckman Coulter) for platelet and monocyte detection, respectively. In all assays, an irrelevant isotype-matched antibody was used as a negative control.
TLR4 expression was analyzed with mAbs anti-TLR4 (Santa Cruz Biotechnology) in platelets stimulated or not with STC of collagen.
Twenty microliters of mAbs were added to 200 lL of platelet suspension (31 to 145 3 10 3 /lL) previously fixed with (2%) paraformaldehyde (0.1% bovine serum albumin) and incubated for 60 minutes at 48C. The unbound mAbs were removed by addition of 0.1% bovine serum albumin-phosphate-buffered saline and centrifugation at 3,000g for 3 minutes (twice). Fluorescence intensity was analyzed on an Epics XL-MCL cytometer (Coulter Electronics) equipped with an argon laser at 488 nm. For every histogram, 50,000 platelets were counted to determine the proportion of positive platelets. Platelets were identified by their forward-scatter and side-scatter characteristics as well as by their binding to CD61. CD14-positive platelets were taken to be platelet-monocyte aggregates and expressed as a percentage of cells. 
Measurement of Intracellular Ca
Platelet CD40L and P-Selectin Assay
Platelet levels of sCD40L and sPs were measured in the supernatant of agonist-stimulated platelets or in citrated blood samples centrifuged for 15 minutes at 3,000g. sCD40L levels were evaluated by a commercial immunoassay (DRG International), and values were expressed as nanograms per milliliter; intra-assay and interassay coefficients of variation were <10%. sPs levels were evaluated by a commercial immunoassay (DRG International), and values were expressed as nanograms per milliliter; intra-assay and interassay coefficients of variation were <10%.
Serum Endotoxin
LPS serum levels were measured by a commercial enzyme-linked immunosorbent assay kit (Cusabio). Antibody specific for LPS was precoated onto a microplate, and 100 lL of standards or sample was plated for 2 hours at room temperature. After incubation, samples were read at 450 nm. Values were expressed as picograms per milliliter; intra-assay and interassay coefficients of variation were 8% and 10%, respectively.
Serum Zonulin
Serum zonulin measurement was performed by enzyme-linked immunosorbent assay (Elabscience). Antibody specific for zonulin was precoated onto a microplate, and 100 lL of standards and patient sera samples were added and incubated for 90 minutes at 378C. Then, a biotinylated detection antibody specific for zonulin and avidin-horseradish peroxidase conjugate was added. The amount of zonulin was measured with a microplate autoreader at 450 nm. Values are expressed as nanograms per milliliter; coefficients of variation were <10%.
Statistics
Categorical variables were reported as counts (percentage) and continuous variables as means 6 standard deviation or median and interquartile range. We tested the independence of categorical variables by the v 2 test and the normal distribution of parameters by the Kolmogorov-Smirnov test. We used the Student unpaired t test and Pearson product-moment correlation analysis to evaluate normally distributed continuous variables. Appropriate nonparametric tests (MannWhitney U test and Spearman rank correlation test) were employed for all other variables.
As an overall nonparametric analysis of variance, the Friedman test for the analysis of intragroup variations was used. In cases of significance, we compared pairrelated samples using the Wilcoxon test. The intergroup analysis was performed with the nonparametric Mann-Whitney U test.
To further analyze the relationship between platelet activation and endotoxin, we ran a multiple regression analysis, considering age, gender, Child-Pugh score, and LPS concentration as possible determinants of sCD40L.
Only two-tailed probabilities were used for testing statistical significance. Probability values <0.05 were regarded as statistically significant. All calculations were made with the computer program Statistica 7 (StatSoft, Tulsa, OK, USA).
Results
Sixty-nine patients with cirrhosis of various causes (alcohol abuse, n 5 24; viral hepatitis, n 5 24; cryptogenic cirrhosis, n 5 12; mixed, n 5 9) were included in the study. Mean age was 62.6 6 13.5, and they were predominantly men (68%).
The patients were classified according to ChildPugh classification (16) ; 35 were of A class, 17 of B class, and 17 of C class. Some patients were hospitalized for a short period as part of a liver transplantscreening program in a single institution (n 5 23, Gastroenterology Unit) at the time of inclusion.
Eighteen patients had a history of a previous upper gastrointestinal bleeding due to esophageal varices rupture. Around one third of LC patients had concomitant diabetes mellitus, and none had hepatorenal syndrome.
Compared to controls, serum levels of LPS (6.0 [4.0-17.5] versus 57.4 [43.4-87.2] pg/mL, P < 0.0001), sCD40L (7.0 6 2.2 versus 24.4 6 13.3 ng/ mL, P < 0.0001), and sPs (14.2 6 4.05 versus 33.2 6 15.2 ng/mL, P < 0.0001) were higher in LC patients.
Among cirrhosis patients, 1 had a prior portal vein thrombotic event and 4 concomitant hepatocellular carcinoma. After excluding these five patients, LPS (57.6 [44.2-91.0] pg/mL, P < 0.0001), sCD40L (21.6 6 13.9 ng/mL, P < 0.0001), and sPs (34.7 6 17.6 ng/mL, P < 0.0001) were still more elevated compared to controls.
To evaluate the relationship among these parameters and the degree of liver failure, we divided the clinical and laboratory characteristics of LC patients according to the Child-Pugh classes (Table 1) .
Among groups, age and sex were similar. As expected, serum albumin was lower and bilirubin was higher in patients included in B1C compared to A class; platelet count was significantly lower in B1C class. LPS, sCD40L, and sPs levels were significantly higher in decompensated patients. Etiology did not differentiate these results. Conversely, patients with ascites (n 5 29) showed significantly higher levels of LPS (67. Univariate correlation analysis demonstrated that levels of sCD40L directly correlated with LPS (r 5 0.55, P < 0.001), sPs (r 5 0.77, P < 0.001), bilirubin (r 5 0.30, P 5 0.13), and prothrombin timeinternational normalized ratio (r 5 0.44, P < 0.001); conversely, levels of sCD40L inversely correlated with platelet count (r 5 20.36, P 5 0.004) and serum albumin concentration (r 5 20.31, P 5 0.009). Moreover, LPS directly correlated with sPs (r 5 0.32, P 5 0.008).
Creatinine serum levels were not significantly correlated with sCD40L (r 5 0.09, P 5 0.456) or sPs (r 5 0.147, P 5 0.229) plasma levels.
No significant correlation between sCD40L or sPs and mean platelet volume (n 5 30) or white blood count cells (n 5 61) was observed in cirrhosis patients (not shown).
A multivariate analysis including sex, age, ChildPugh score, and LPS was performed to evaluate the independence of correlations. The multivariate analysis showed that LPS (beta-coefficient 5 0.43, P < 0.0001) and Child-Pugh score (beta-coefficient 5 0.28, P 5 0.010) independently predicted sCD40L levels.
Serum levels of zonulin were significantly higher in patients compared to controls (2.54 6 0.94 versus 1.87 6 0.84 ng/mL, P < 0.006). Among Child-Pugh B1C patients, LPS and zonulin were significantly correlated (r 5 0.48, P < 0.05); conversely, no correlation among Child-Pugh A patients (r 5 0.01, p >0.05) was observed.
EX VIVO STUDY
Among the 25 subjects investigated serum LPS was 29.1 6 28.9 pg/mL in controls (n 5 10) and 85.67 6 80.5 pg/mL in cirrhosis patients (n 5 15). The etiology of cirrhosis patients was from alcohol abuse (n 5 1), viral hepatitis (n 5 12), cryptogenic cirrhosis (n 5 11), and mixed (n 5 1); 8 were B and 7 C according to Child-Pugh class. Compared to controls, platelets from cirrhosis patients with STC of agonists showed significantly higher rates of PA (10.0 6 1.41% versus 18.4 6 5.0%, P 5 0.0001) (Fig. 1A,B ) and enhanced release of sCD40L (7.2 6 1.6 ng/mL versus 14.3 6 2.7 ng/mL, P < 0.0001) (Fig. 1C) and sPs (5.6 6 1.2 ng/mL versus 15.563.2 ng/mL, P < 0.0001) (Fig.  1D) ; these changes were inhibited by platelet treatment with TLR4bp (Fig. 1A-D) . No differences in aggregation curves were detected in patients and controls when platelets were stimulated with TC of agonist: addition of TLR4bp-inhibited agonists induced PA only in platelets from cirrhosis patients (Fig.  1A,B) .
We also evaluated in vivo platelet activation by measuring platelet-monocyte complex. Compared to platelets from controls, platelets from cirrhosis patients showed a higher complex (Fig. 1E ). Moreover, STC was able to increase TLR4 receptor expression and Ca 21 mobilization in platelets from cirrhosis patients compared to controls ( Fig. 2A,B) .
We also analyzed the platelet response to STC in LC patients with a platelet count <50 3 10 3 /lL (etiology was from viral hepatitis in 5 patients and mixed in 1 patient; 2 were B and 4 C according to ChildPugh class) and in controls. Compared to controls, cirrhosis patients with low platelet count showed a higher PA, sCD40L, and sPs release (Fig. 3A-C) . Platelet incubation with TLR4bp blunted PA in cirrhosis patients (Fig. 3A-C) .
IN VITRO STUDY
LPS alone was unable to activate platelets from HS even at the highest concentration (data not shown). Conversely, in platelets with STC of collagen, LPS dose-dependently amplified PA and significantly increased sCD40L and sPs release (all P < 0.001) 
FIG. 1. LPS and platelet activation in LC patients (closed circles) and controls (open circles)
. Platelets were stimulated with or without STC (0.25 lg/mL) or TC (2 lg/mL) of collagen in the presence or not of TLR4 inhibitor (4 lM) or control peptide (4 lM) for the evaluation of platelet aggregation (A) and platelet release of sCD40L levels (C) and sPs levels (D) (n 5 15 for patients and n 5 10 for controls; *P < 0.01). Representative tracing curves of aggregation tests performed with TC and STC of agonists in the presence of absence of TLR4 antagonists in patients and controls (B). Platelet-monocyte complex in patients (n 5 15) and controls (n 5 10) (*P < 0.01) (E). Abbreviation: CP, control peptide.
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( Fig. 4A-C) . Amplification of the platelet response by LPS was blunted in platelets pretreated with TLR4bp (all P < 0.001) (Fig. 4A-C) . Similar data were obtained with ADP (not shown).
Discussion
The study provides the first evidence that platelet activation in cirrhosis may be a consequence of enhanced LPS circulating levels. LPS is suggested to play a role for several reasons: (1) LPS is elevated in cirrhosis and significantly correlated with markers of in vivo platelet activation; (2) increased ex vivo PA is blunted by platelet treatment with TLR4, which is a specific platelet LPS receptor; (3) in vitro study with LPS concentration in the same range detected in the peripheral circulation of cirrhosis patients amplifies platelet response to common agonists in normal platelets.
Previous studies suggested the existence of a thrombocytopathy in cirrhosis, which could potentially predispose to bleeding.
(1) The existence of such a platelet abnormality has been recently challenged because primary hemostasis is normal in cirrhosis and, overall, does not predict bleeding. (2, 3) Furthermore, previous data regarding platelet function in cirrhosis provide conflicting results. In particular, ex vivo aggregation tests reporting impaired platelet aggregation and impaired release of aggregating molecules such as ADP are difficult to interpret because of the technical issue related to performing aggregation tests in patients with low platelet count. (17, 18) Under this circumstance, platelet count adjustment is crucial, but previous studies did not specify if and how this critical problem has been overcome. (17, 18) Also, in contrast to these previous data, cirrhosis patients display enhanced urinary excretion of 11-dehydrothromboxane B 2 , suggesting that platelet function in cirrhosis patients may be increased. (19) In accordance with this, recent studies drew attention to the fact that cirrhosis is associated with chronic inflammation, which may be a trigger for PA. (9, 13) Thus, we demonstrated that Nox2-derived oxidative stress might be responsible for platelet overproduction of isoprostanes, which are chemically stable eicosanoids with a proaggregating property. (8, 9) Consistent with this, we found elevated circulating markers of in vivo platelet activation, such as sPs and sCD40L, which reinforced the hypothesis of platelet hyperactivation in vivo. (14, (20) (21) (22) (23) This finding is apparently in contrast with a previous study showing normal levels of plasma P-selectin in 16 cirrhosis patients compared to controls; however, when sPs was adjusted for platelet count, a significant increase was detected. (24) Enhanced in vivo platelet activation was corroborated by several ex vivo tests such as platelet interaction with monocytes, which, in fact, was more elevated in cirrhosis patients compared to controls. Furthermore, we performed aggregation tests using TC of agonists, which, at variance with previous reports, did not show a difference with controls. However, as the use of TC of agonists could be not sensitive enough to demonstrate platelet hyperaggregation, we performed experiments with STC of agonists, which demonstrated a more elevated sensitivity to the agonists in cirrhosis patients compared to controls. This prompted us to speculate on the existence in the medium of molecules which could increase platelet sensitivity to the agonist.
Bacterial LPS is elevated in cirrhosis, particularly in decompensated cirrhosis, with a mechanism related to enhanced gut permeability and ensuing translocation of LPS in the peripheral circulation. (6, 25) Consistent with our previous report, the present study shows that cirrhosis is associated with low-grade endotoxemia, which is more evident in Child-Pugh classes B and C. Of note, LPS significantly correlated with sCD40L and sPs, suggesting a role for LPS in eliciting platelet activation. There are several reports, which showed, even if not unequivocally, that LPS is a trigger for PA (10) (11) (12) (13) ; a potential drawback of these studies is in the use of supraphysiologic concentrations of LPS, i.e., at least 4-fold to 5-fold higher than physiologic ones. Using LPS concentrations in the order of picograms per milliliter, we observed in vitro that LPS per se is not an aggregating molecule but amplifies the platelet response to the common agonists by interacting with TLR4. This was demonstrated with several methodological approaches including analysis of PA and release of sCD40L and sPs by activated cells. In particular, ex vivo aggregation tests demonstrated a role for LPS as a trigger of platelet activation as a TLR4 inhibitor blunted platelet aggregation by STC and TC of agonists in cirrhosis patients displaying elevated blood levels of LPS. Together these data suggest that, in a medium containing elevated LPS, platelets are more responsive to agonists compared to controls; the hypothesis is supported by the fact that ex vivo PA was inhibited by platelet incubation with TLR4. We also investigated if ex vivo PA could be influenced by changes of platelet count; of interest is the fact that, even in presence of a platelet count of <50 3 10 3 /lL, ex vivo PA was increased compared to control.
Studies have demonstrated that liver cirrhosis is associated with enhanced gut permeability, which may account for LPS translocation into the systemic circulation. (26, 27) To further address this issue, we measured circulating levels of zonulin, which modulates gut permeability by disassembling the intercellular tight junctions. (28, 29) Experimental and clinical studies demonstrated that zonulin up-regulation plays a role in increasing gut permeability and that serum level of zonulin correlates with enhanced intestinal permeability. (28, 29) Compared to controls, serum levels of zonulin were increased in the entire cohort, suggesting a role for gut permeability in enhancing circulating levels of LPS; however, we cannot exclude other mechanisms as patients in Child-Pugh A class disclosed higher values of LPS but only a small increase of serum zonulin.
The study has implications and limitations. In addition to other putative mechanisms accounting for platelet activation such as enhanced thrombin generation or increased levels of von Willebrand factor, (30, 31) LPS may represent a novel pathway triggering platelet activation in LC. The present article does not fully support the hypothesis that LPS elicits PA in vivo; an interventional study showing that LPS lowering is associated with PA reduction is necessary to fully support that LPS promotes PA in vivo. Furthermore, we cannot fully exclude that the enhanced circulating levels of CD40L and P-selectin reflect impaired clearance by liver failure. The fact that cirrhosis patients have platelets hyperreactive to common agonists challenges the need to increase the platelet number to reduce the risk of bleeding and may account for the increased thrombotic risk observed with eltrombopag, a thrombopoietin mimetic. (32) In addition to systemic clotting activation, platelet hyperreactivity may represent another mechanism accounting for the enhanced thrombotic risk of cirrhosis patients.
In conclusion, our study shows that platelets from cirrhosis patients are more reactive to common agonists compared to normal platelets and suggests a role for LPS in triggering PA. Interventional trials to modulate low-grade endotoxemia are warranted to assess if this therapeutic approach may reduce platelet activation in cirrhosis.
